This Month in Psychopharmacology

World Suicide Prevention Day

Education matters for suicide prevention. National and regional sui...

Read More

Lithium Treatment May be Associated With Lower Cardiovascular Risk in Bipolar Disorder

Lithium remains a first-line treatment with established benefits fo...

Read More

SGLT2 Inhibitor Use Associated With Lower Dementia Risk in Older Adults With Psychiatric Disorders

A recent study suggest that sodium-glucose cotransporter 2 (SGLT2) ...

Read More

Suicide Prevention: Cross-Diagnostic Strategies in Clinical Care

Join us at the 2026 NEI Fall Congress, for a CME/CE session presen...

Read More

GLP-1 Receptor Agonists Are Associated With Lower Mortality in Serious Mental Illness

People with serious mental illness (SMI) die 10 to 25 years earlier...

Read More

Treating Parental ADHD May Strengthen Behavioral Intervention for Young Children

Attention-deficit/hyperactivity disorder (ADHD) is highly heritable...

Read More

Benzodiazepine Trends Reveal Persistent Challenges in Older Adult Care

Benzodiazepines are often prescribed to older adults for anxiety an...

Read More

DT120 (Lysergide) Shows Positive Phase 3 Results in Generalized Anxiety Disorder

Definium Therapeutics reported positive Phase 3 topline results for...

Read More

Long-Acting Injectable Antipsychotics Linked to Lower Early Rehospitalization in Bipolar I Disorder

Long-acting injectable antipsychotics were associated with modestly...

Read More

FDA Approves First-in-Class Orexin Agonist for Narcolepsy Type 1

The U.S. Food and Drug Administration has approved oveporexton, an ...

Read More

Novel M1/M4 Agonist Demonstrates Phase 2 Efficacy in Schizophrenia

An oral, extended-release, fixed-dose combination of betovumeline, ...

Read More

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

The U.S. Food and Drug Administration has approved centanafadine, a...

Read More